Market closed
SELLAS Life Sciences/$SLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About SELLAS Life Sciences
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Ticker
$SLS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15
Website
SLS Metrics
BasicAdvanced
$127M
-
-$0.50
2.44
-
Price and volume
Market cap
$127M
Beta
2.44
52-week high
$1.47
52-week low
$0.95
Average daily volume
1.1M
Financial strength
Current ratio
1.717
Quick ratio
1.46
Long term debt to equity
4.828
Total debt to equity
10.576
Management effectiveness
Return on assets (TTM)
-153.57%
Return on equity (TTM)
-4,147.88%
Valuation
Price to book
10.94
Price to tangible book (TTM)
13.72
Price to free cash flow (TTM)
-2.42
Growth
Earnings per share change (TTM)
-62.47%
3-year earnings per share growth (CAGR)
-27.74%
SLS News
AllArticlesVideos
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·5 days ago
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
GlobeNewsWire·3 weeks ago
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst
Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for SELLAS Life Sciences stock?
SELLAS Life Sciences (SLS) has a market cap of $127M as of April 28, 2025.
What is the P/E ratio for SELLAS Life Sciences stock?
The price to earnings (P/E) ratio for SELLAS Life Sciences (SLS) stock is 0 as of April 28, 2025.
Does SELLAS Life Sciences stock pay dividends?
No, SELLAS Life Sciences (SLS) stock does not pay dividends to its shareholders as of April 28, 2025.
When is the next SELLAS Life Sciences dividend payment date?
SELLAS Life Sciences (SLS) stock does not pay dividends to its shareholders.
What is the beta indicator for SELLAS Life Sciences?
SELLAS Life Sciences (SLS) has a beta rating of 2.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.